Let me search for the specific litigation and corporate financials.
Wockhardt USA LLC (formerly Wockhardt USA, Inc.) is the U.S. subsidiary of Wockhardt Limited, an Indian pharmaceutical and biotechnology company founded in 1967 and headquartered in Mumbai. Wockhardt USA was formed in 2004, is incorporated in Delaware, and was headquartered at 20 Waterview Blvd., Parsippany, New Jersey. It is a wholly owned, indirect subsidiary of the listed parent (BSE: 532300 / NSE: WOCKPHARMA) through Wockhardt Bio AG. The parent reported roughly 4,100 employees and trailing revenue near US$390 million (about ₹3,300 crore), with a market capitalization in the low billions of dollars; Wockhardt USA historically represented a fifth or more of group business.
Products / operations. Wockhardt USA marketed generic prescription pharmaceuticals in the U.S. — oral solids, oral liquids, topicals, and sterile injectables — with more than 110 ANDA approvals and several hundred NDCs across dozens of product families (e.g., donepezil, levofloxacin, venlafaxine ER, granisetron and octreotide injections). It sold through the October 2007 acquisition of Morton Grove Pharmaceuticals, which supplies oral liquids and topicals. In July 2025 Wockhardt Limited announced voluntary Chapter 7 liquidation of Wockhardt USA LLC and Morton Grove Pharmaceuticals, exiting legacy U.S. generics to concentrate on antibiotics and insulin.
Litigation posture. The case data show one tracked matter, with Wockhardt USA as defendant and zero plaintiff filings — the profile of an operating company defending an infringement suit, not a patent asserter. The venue is the Southern District of Indiana, Indianapolis Division, the home forum of Eli Lilly, not a plaintiff-friendly NPE district such as the Eastern District of Texas.
Notable case. Eli Lilly and Company v. Wockhardt Limited et al. (No. 1:08-cv-01547, S.D. Ind., filed November 14, 2008) was a Hatch-Waxman action over Wockhardt's ANDA for generic duloxetine hydrochloride, a copy of Lilly's Cymbalta. The court entered final judgment for Lilly in March 2011, and an April 2011 order barred generic duloxetine sales during the compound patent's term. Wockhardt also faced other brand-holder ANDA suits (e.g., Orion's Stalevo, Sepracor's Lunesta) in that period.